References
- 1.LIU F F, ZOU Z S, SHEN L J, et al. A prediction model for outcome in patients with HBV-ACLF based on predisposition, injury, response and organ failure[J]. Sci Rep, 2020, 10(1): 20176.
- 2.Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44.
- 3.SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe cute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391.
- 4.MAHMUD N, KAPLAN D E, TADDEI T H, et al. Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis[J]. Hepatology, 2019, 69(5): 2150-2163.
- 5.HERNAEZ R, KRAMER J R, LIU Y, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA[J]. J Hepatol, 2019, 70(4): 639-647.
- 6.BERNAL W, JALAN R, QUAGLIA A, et al. Acute-on-chronic liver failure[J]. Lancet, 2015, 386(10003): 1576-1587.
- 7.LI J, LIANG X, JIANG J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2021, 71(1): 163-175.
- 8.NORLANDER A E, BLOODWORTH M H, TOKI S, et al. Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming[J]. J Clin Invest, 2021,131(7): e140690.
- 9.TAN N H, CHEN B, PENG J, et al. Expression of Treg/Th17 cells in patients with HBV-ACLF in different traditional Chinese medicine syndrome "Yanghuang-Yinyanghuang-Yinhuang"[J]. Chin J Exp Tradit Med Form, 2020, 26(2): 33-38.
- 10.WANG X B, WANG X J, LIU H M, et al. Guidelines for the integrated traditional Chinese and Western medicine diagnosis and treatment of acute-on-chronic liver failure[J]. J Clin Hepatol, 2023, 39(7): 1547-1552.
- 11.XU R Z, LI Y. On the relationship between strengthening the body resistance and eliminating pathogenic factors and immunity in traditional Chinese medicine for tumor treatment[J]. Liaoning J Tradit Chin Med, 2018, 45(9): 1858-1859.
- 12.YANG L H, HU K W, WANG J X. Mechanism of therapeutic methods of activating blood, resolving phlegm, and removing toxins in liver cancer based on immune microenvironment[J]. Chin J Exp Tradit Med Form, 2022, 28(14): 172-178.
- 13.ZHAI S, ZHANG L, DANG S, et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure[J]. Viral Immunol, 2011, 24(4): 303-310.
- 14.VITALES-NOYOLA M, LAYSECA-ESPINOSA E, BARANDA L, et al. Analysis of sodium chloride intake and Treg/Th17 lymphocytes in healthy individuals and patients with rheumatoid arthritis or systemic lupus erythematosus[J]. J Immunol Res, 2018, 2018: 9627806.
- 15.SINGH R P, HASAN S, SHARMA S, et al. Th17 cells in inflammation and autoimmunity[J]. Autoimmun Rev, 2014, 13(12): 1174-1181.
- 16.PATRIZIA F, MARTIN S, WINFRIED G, et al. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders[J]. Molecules, 2017, 22(1): 134.
- 17.WANG J, LI C, FU J, et al.Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B[J]. Scand J Immunol, 2019, 89(5): e12755.
- 18.LIANG X S, LI C Z, ZHOU Y, et al. Changes in circulating FoxP3+ regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2014, 20(26): 8558-8571.
- 19.LAN Y T, WANG Z L, TIAN P, et al. Treg/Th17 imbalance and its clinical significance in patients with hepatitis B-associated liver cirrhosis[J]. Diagn Pathol, 2019, 14(1): 114.
- 20.KUN L, HUAIE L, TAO G. Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients[J]. Clin Res Hepatol Gastroenterol, 2017, 41(4): 399-407.


